The early seeds of AstraZeneca’s collaboration with Hutchison MediPharma in China were sown by our scientists in Shanghai, through their relationships within the local scientific community.
An early exchange of ideas and a Hutchison presentation of its early pipeline prompted our interest in a novel oncology compound – a potent ATP-competitive c-Met inhibitor. In December 2011, we signed a global licensing, co-development and commercialisation agreement for the compound. It is being developed as an oral drug for the treatment of solid tumours. Six clinical studies are currently running across several countries, with clinical activity observed in kidney, lung, stomach and colon cancers.